Company intelligence
First Tracks Biotherapeutics
Carving a new trail in immunology
Biotechnology Research
San Diego, US
73 employees
Founded 2026
2 public signals
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
Verified activity
Signals from First Tracks Biotherapeutics
2 published signals
Presence & Recognition
First Tracks Biotherapeutics featured Peter Light, CPA in the People You Meet on the Trail Employee Spotlight series
Reported by First Tracks Biotherapeutics
Research & Knowledge
First Tracks Biotherapeutics is developing an investigational anti-CD122 antagonist ANB033 to block IL-15 and IL-2 signals driving inflammation.
Reported by First Tracks Biotherapeutics